China's National Medical Products Administration (NMPA) has granted emergency approval to Shanghai Fosun Long March Medical Science Co Ltd, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd (Stock Code: 600196.SH, 02196.HK), for its self-developed novel coronavirus nucleic acid detection kit, it was reported on Thursday.
According to the company, this kit can realise qualitative detection of novel coronavirus ORF1ab, N and E gene targets and can complete the detection of 96 samples within two hours by supporting fast nucleic acid extraction instrument and extraction reagents. It is also claimed to decrease the risk of operator infection, reduce the risk of cross contamination in the laboratory, and improve detection efficiency.
The company said that it has paid close attention to the development of the epidemic since the outbreak of COVID-19, based on its perennial provision of speedy test reagents for Type A&B flu and common respiratory viruses.
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Neola Medical secures US patent for disposable lung monitoring probes
Spinogenix reports approval of 'tazbentetol' as non-proprietary name for SPG302
Polarean expands XENOVIEW 3T Coil access with Philips compatibility
Immedica gets UAE approval for Zepzelca maintenance treatment